Q&A: Through robotics, Fred Parietti and team look to fix cell therapy's future
There’s a bottleneck in manufacturing right now, and perhaps the category that is the best representative of the issue is cell and gene therapy. Several companies are trying different things to address the issue, but Multiply Labs has enlisted some CDMO powerhouses on its path toward the automation of the process.
Cytiva and the University of California-San Francisco were already members of the robotic cell therapy manufacturing consortium Multiply, founded in 2021. Last week, it was announced that Thermo Fisher Scientific and Charles River Laboratories have joined the team to help develop a cGMP-compliant system that can make gene-modified cell therapies at an individual scale.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.